{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:07:34Z","timestamp":1791587254748,"version":"4.3.4"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100009726","name":"Foundation for Angelman Syndrome Therapeutics","doi-asserted-by":"publisher","award":["PD2023-001"],"award-info":[{"award-number":["PD2023-001"]}],"id":[{"id":"10.13039\/100009726","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009726","name":"Foundation for Angelman Syndrome Therapeutics","doi-asserted-by":"publisher","award":["FT2024-001"],"award-info":[{"award-number":["FT2024-001"]}],"id":[{"id":"10.13039\/100009726","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009726","name":"Foundation for Angelman Syndrome Therapeutics","doi-asserted-by":"publisher","award":["FT2022-005"],"award-info":[{"award-number":["FT2022-005"]}],"id":[{"id":"10.13039\/100009726","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Molecular Autism"],"DOI":"10.1186\/s13229-025-00690-0","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T08:12:45Z","timestamp":1764231165000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["UBE3A stabilization of \u03b2-catenin preserves synaptic proteins essential for motor and cognitive functions in Angelman Syndrome"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2153-256X","authenticated-orcid":false,"given":"Xin","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4082-8008","authenticated-orcid":false,"given":"Yuwen-Alvin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"690_CR1","doi-asserted-by":"crossref","unstructured":"Owais A, Mishra RK, Kiyokawa H. The HECT E3 ligase E6AP\/UBE3A as a therapeutic target in cancer and neurological disorders. Cancers (Basel), 2020. 12(8).","DOI":"10.3390\/cancers12082108"},{"issue":"4","key":"690_CR2","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/S0896-6273(00)80596-6","volume":"21","author":"YH Jiang","year":"1998","unstructured":"Jiang YH, et al. Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation. Neuron. 1998;21(4):799\u2013811.","journal-title":"Neuron"},{"issue":"1","key":"690_CR3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/ng0197-70","volume":"15","author":"T Kishino","year":"1997","unstructured":"Kishino T, Lalande M, Wagstaff J. UBE3A\/E6-AP mutations cause Angelman syndrome. Nat Genet. 1997;15(1):70\u20133.","journal-title":"Nat Genet"},{"issue":"1","key":"690_CR4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/ng0197-74","volume":"15","author":"T Matsuura","year":"1997","unstructured":"Matsuura T, et al. De Novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome. Nat Genet. 1997;15(1):74\u20137.","journal-title":"Nat Genet"},{"issue":"4","key":"690_CR5","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/ajmg.c.30278","volume":"154C","author":"CA Williams","year":"2010","unstructured":"Williams CA. The behavioral phenotype of the Angelman syndrome. Am J Med Genet C Semin Med Genet. 2010;154\u00a0C(4):432\u20137.","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"2","key":"690_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.nbd.2008.08.011","volume":"38","author":"A Hogart","year":"2010","unstructured":"Hogart A, et al. The comorbidity of autism with the genomic disorders of chromosome 15q11.2-q13. Neurobiol Dis. 2010;38(2):181\u201391.","journal-title":"Neurobiol Dis"},{"issue":"7","key":"690_CR7","doi-asserted-by":"publisher","first-page":"p689","DOI":"10.1002\/humu.22800","volume":"36","author":"A Noor","year":"2015","unstructured":"Noor A, et al. 15q11.2 duplication encompassing only the UBE3A gene is associated with developmental delay and neuropsychiatric phenotypes. Hum Mutat. 2015;36(7):p689\u201393.","journal-title":"Hum Mutat"},{"issue":"7246","key":"690_CR8","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/nature07953","volume":"459","author":"JT Glessner","year":"2009","unstructured":"Glessner JT, et al. Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature. 2009;459(7246):569\u201373.","journal-title":"Nature"},{"issue":"30","key":"690_CR9","doi-asserted-by":"publisher","first-page":"12503","DOI":"10.1074\/jbc.M117.788448","volume":"292","author":"JJ Yi","year":"2017","unstructured":"Yi JJ, et al. The autism-linked UBE3A T485A mutant E3 ubiquitin ligase activates the Wnt\/beta-catenin pathway by inhibiting the proteasome. J Biol Chem. 2017;292(30):12503\u201315.","journal-title":"J Biol Chem"},{"issue":"4","key":"690_CR10","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.cell.2015.06.045","volume":"162","author":"JJ Yi","year":"2015","unstructured":"Yi JJ, et al. An Autism-Linked mutation disables phosphorylation control of UBE3A. Cell. 2015;162(4):795\u2013807.","journal-title":"Cell"},{"issue":"12","key":"690_CR11","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1093\/hmg\/ddab104","volume":"30","author":"A Adhikari","year":"2021","unstructured":"Adhikari A, et al. Functional rescue in an Angelman syndrome model following treatment with lentivector transduced hematopoietic stem cells. Hum Mol Genet. 2021;30(12):1067\u201383.","journal-title":"Hum Mol Genet"},{"issue":"3","key":"690_CR12","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/mt.2015.236","volume":"24","author":"BJ Bailus","year":"2016","unstructured":"Bailus BJ, et al. Protein delivery of an artificial transcription factor restores widespread Ube3a expression in an Angelman syndrome mouse brain. Mol Ther. 2016;24(3):548\u201355.","journal-title":"Mol Ther"},{"issue":"11","key":"690_CR13","doi-asserted-by":"publisher","first-page":"4122","DOI":"10.1016\/j.ymthe.2024.09.032","volume":"32","author":"HO Bazick","year":"2024","unstructured":"Bazick HO, et al. AAV vector-derived elements integrate into Cas9-generated double-strand breaks and disrupt gene transcription. Mol Ther. 2024;32(11):4122\u201337.","journal-title":"Mol Ther"},{"issue":"3","key":"690_CR14","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s13311-021-01082-x","volume":"18","author":"NA Copping","year":"2021","unstructured":"Copping NA, et al. Emerging gene and small molecule therapies for the neurodevelopmental disorder Angelman syndrome. Neurotherapeutics. 2021;18(3):1535\u201347.","journal-title":"Neurotherapeutics"},{"issue":"688","key":"690_CR15","doi-asserted-by":"publisher","first-page":"eabf4077","DOI":"10.1126\/scitranslmed.abf4077","volume":"15","author":"SV Dindot","year":"2023","unstructured":"Dindot SV, et al. An ASO therapy for Angelman syndrome that targets an evolutionarily conserved region at the start of the UBE3A-AS transcript. Sci Transl Med. 2023;15(688):eabf4077.","journal-title":"Sci Transl Med"},{"key":"690_CR16","doi-asserted-by":"crossref","unstructured":"Huie EZ, et al. Peptidomimetic inhibitors targeting TrkB\/PSD-95 signaling improves cognition and seizure outcomes in an Angelman syndrome mouse model. Neuropsychopharmacology, 2024.","DOI":"10.1101\/2024.06.07.597833"},{"key":"690_CR17","doi-asserted-by":"publisher","first-page":"102899","DOI":"10.1016\/j.conb.2024.102899","volume":"88","author":"JC Krzeski","year":"2024","unstructured":"Krzeski JC, Judson MC, Philpot BD. Neuronal UBE3A substrates hold therapeutic potential for Angelman syndrome. Curr Opin Neurobiol. 2024;88:102899.","journal-title":"Curr Opin Neurobiol"},{"key":"690_CR18","doi-asserted-by":"publisher","first-page":"102513","DOI":"10.1016\/j.pneurobio.2023.102513","volume":"230","author":"KA Lau","year":"2023","unstructured":"Lau KA, et al. A PSD-95 peptidomimetic mitigates neurological deficits in a mouse model of Angelman syndrome. Prog Neurobiol. 2023;230:102513.","journal-title":"Prog Neurobiol"},{"key":"690_CR19","doi-asserted-by":"crossref","unstructured":"Milazzo C, et al. Antisense oligonucleotide treatment rescues UBE3A expression and multiple phenotypes of an Angelman syndrome mouse model. JCI Insight, 2021. 6(15).","DOI":"10.1172\/jci.insight.145991"},{"issue":"4","key":"690_CR20","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s13311-022-01239-2","volume":"19","author":"AW Nenninger","year":"2022","unstructured":"Nenninger AW, et al. Improving gene therapy for Angelman syndrome with secreted human UBE3A. Neurotherapeutics. 2022;19(4):1329\u201339.","journal-title":"Neurotherapeutics"},{"issue":"4","key":"690_CR21","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.ymthe.2023.01.013","volume":"31","author":"H O\u2019Geen","year":"2023","unstructured":"O\u2019Geen H, et al. Transcriptional reprogramming restores UBE3A brain-wide and rescues behavioral phenotypes in an Angelman syndrome mouse model. Mol Ther. 2023;31(4):1088\u2013105.","journal-title":"Mol Ther"},{"issue":"8","key":"690_CR22","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1038\/s41380-023-02208-7","volume":"28","author":"SE Wang","year":"2023","unstructured":"Wang SE, Jiang YH. Novel epigenetic molecular therapies for imprinting disorders. Mol Psychiatry. 2023;28(8):3182\u201393.","journal-title":"Mol Psychiatry"},{"issue":"6","key":"690_CR23","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1002\/jnr.24576","volume":"98","author":"X Yang","year":"2020","unstructured":"Yang X. Towards an Understanding of Angelman syndrome in mice studies. J Neurosci Res. 2020;98(6):1162\u201373.","journal-title":"J Neurosci Res"},{"issue":"8","key":"690_CR24","doi-asserted-by":"publisher","first-page":"e70559","DOI":"10.1096\/fj.202403130RR","volume":"39","author":"S Qu","year":"2025","unstructured":"Qu S, et al. Dietary intake of octanoic acid restores UBE3A expression and improves the behavioral phenotypes in a mouse model of Angelman syndrome. FASEB J. 2025;39(8):e70559.","journal-title":"FASEB J"},{"issue":"22","key":"690_CR25","doi-asserted-by":"publisher","first-page":"3842","DOI":"10.1093\/hmg\/ddz221","volume":"28","author":"SJ Lopez","year":"2019","unstructured":"Lopez SJ, et al. Imprinting effects of UBE3A loss on synaptic gene networks and Wnt signaling pathways. Hum Mol Genet. 2019;28(22):3842\u201352.","journal-title":"Hum Mol Genet"},{"issue":"2","key":"690_CR26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.tins.2013.11.005","volume":"37","author":"N Krumm","year":"2014","unstructured":"Krumm N, et al. A de Novo convergence of autism genetics and molecular neuroscience. Trends Neurosci. 2014;37(2):95\u2013105.","journal-title":"Trends Neurosci"},{"issue":"11","key":"690_CR27","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/s41419-020-03228-9","volume":"11","author":"CC Chiu","year":"2020","unstructured":"Chiu CC, et al. (D620N) VPS35 causes the impairment of Wnt\/beta-catenin signaling cascade and mitochondrial dysfunction in a PARK17 knockin mouse model. Cell Death Dis. 2020;11(11):1018.","journal-title":"Cell Death Dis"},{"issue":"1","key":"690_CR28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.neuron.2014.08.048","volume":"84","author":"CC Liu","year":"2014","unstructured":"Liu CC, et al. Deficiency in LRP6-mediated Wnt signaling contributes to synaptic abnormalities and amyloid pathology in alzheimer\u2019s disease. Neuron. 2014;84(1):63\u201377.","journal-title":"Neuron"},{"issue":"1","key":"690_CR29","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41398-018-0231-6","volume":"8","author":"C Elliott","year":"2018","unstructured":"Elliott C, et al. A role for APP in Wnt signalling links synapse loss with beta-amyloid production. Transl Psychiatry. 2018;8(1):179.","journal-title":"Transl Psychiatry"},{"issue":"2","key":"690_CR30","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/sj.mp.4001208","volume":"8","author":"GV De Ferrari","year":"2003","unstructured":"De Ferrari GV, et al. Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils. Mol Psychiatry. 2003;8(2):195\u2013208.","journal-title":"Mol Psychiatry"},{"issue":"1","key":"690_CR31","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.neuropharm.2011.08.032","volume":"62","author":"KA Maguschak","year":"2012","unstructured":"Maguschak KA, Ressler KJ. The dynamic role of beta-catenin in synaptic plasticity. Neuropharmacology. 2012;62(1):78\u201388.","journal-title":"Neuropharmacology"},{"issue":"4","key":"690_CR32","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1172\/JCI70372","volume":"124","author":"V Tucci","year":"2014","unstructured":"Tucci V, et al. Dominant beta-catenin mutations cause intellectual disability with recognizable syndromic features. J Clin Invest. 2014;124(4):1468\u201382.","journal-title":"J Clin Invest"},{"issue":"17","key":"690_CR33","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1093\/hmg\/ddz115","volume":"28","author":"RJ Wickham","year":"2019","unstructured":"Wickham RJ, et al. Learning impairments and molecular changes in the brain caused by beta-catenin loss. Hum Mol Genet. 2019;28(17):2965\u201375.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"690_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41392-021-00762-6","volume":"7","author":"J Liu","year":"2022","unstructured":"Liu J, et al. Wnt\/beta-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther. 2022;7(1):3.","journal-title":"Signal Transduct Target Ther"},{"key":"690_CR35","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1146\/annurev-biochem-040320-103615","volume":"91","author":"EY Rim","year":"2022","unstructured":"Rim EY, Clevers H, Nusse R. The Wnt pathway: from signaling mechanisms to synthetic modulators. Annu Rev Biochem. 2022;91:571\u201398.","journal-title":"Annu Rev Biochem"},{"issue":"12","key":"690_CR36","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1038\/nn.2226","volume":"11","author":"AA Gulacsi","year":"2008","unstructured":"Gulacsi AA, Anderson SA. Beta-catenin-mediated Wnt signaling regulates neurogenesis in the ventral telencephalon. Nat Neurosci. 2008;11(12):1383\u201391.","journal-title":"Nat Neurosci"},{"issue":"11","key":"690_CR37","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1038\/nn1132","volume":"6","author":"X Yu","year":"2003","unstructured":"Yu X, Malenka RC. Beta-catenin is critical for dendritic morphogenesis. Nat Neurosci. 2003;6(11):1169\u201377.","journal-title":"Nat Neurosci"},{"issue":"11","key":"690_CR38","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1038\/nn.2198","volume":"11","author":"KA Maguschak","year":"2008","unstructured":"Maguschak KA, Ressler KJ. Beta-catenin is required for memory consolidation. Nat Neurosci. 2008;11(11):1319\u201326.","journal-title":"Nat Neurosci"},{"issue":"1","key":"690_CR39","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1038\/s41467-020-15073-7","volume":"11","author":"GR Buel","year":"2020","unstructured":"Buel GR, et al. Structure of E3 ligase E6AP with a proteasome-binding site provided by substrate receptor hRpn10. Nat Commun. 2020;11(1):1291.","journal-title":"Nat Commun"},{"key":"690_CR40","doi-asserted-by":"publisher","first-page":"534","DOI":"10.3389\/fphys.2019.00534","volume":"10","author":"N Elu","year":"2019","unstructured":"Elu N, et al. Detailed dissection of UBE3A-Mediated DDI1 ubiquitination. Front Physiol. 2019;10:534.","journal-title":"Front Physiol"},{"issue":"47","key":"690_CR41","doi-asserted-by":"publisher","first-page":"18387","DOI":"10.1074\/jbc.RA118.004653","volume":"293","author":"S Kuhnle","year":"2018","unstructured":"Kuhnle S, et al. Angelman syndrome-associated point mutations in the Zn(2+)-binding N-terminal (AZUL) domain of UBE3A ubiquitin ligase inhibit binding to the proteasome. J Biol Chem. 2018;293(47):18387\u201399.","journal-title":"J Biol Chem"},{"issue":"14","key":"690_CR42","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1007\/s00018-013-1526-7","volume":"71","author":"SY Lee","year":"2014","unstructured":"Lee SY, et al. Ube3a, the E3 ubiquitin ligase causing Angelman syndrome and linked to autism, regulates protein homeostasis through the proteasomal shuttle Rpn10. Cell Mol Life Sci. 2014;71(14):2747\u201358.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"690_CR43","doi-asserted-by":"publisher","first-page":"e1625","DOI":"10.1038\/cddis.2014.572","volume":"6","author":"V Tomaic","year":"2015","unstructured":"Tomaic V, Banks L. Angelman syndrome-associated ubiquitin ligase UBE3A\/E6AP mutants interfere with the proteolytic activity of the proteasome. Cell Death Dis. 2015;6(1):e1625.","journal-title":"Cell Death Dis"},{"issue":"19","key":"690_CR44","doi-asserted-by":"publisher","first-page":"12622","DOI":"10.1074\/jbc.M900556200","volume":"284","author":"T Uchiki","year":"2009","unstructured":"Uchiki T, et al. The ubiquitin-interacting motif protein, S5a, is ubiquitinated by all types of ubiquitin ligases by a mechanism different from typical substrate recognition. J Biol Chem. 2009;284(19):12622\u201332.","journal-title":"J Biol Chem"},{"key":"690_CR45","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13229-018-0231-7","volume":"9","author":"M Sonzogni","year":"2018","unstructured":"Sonzogni M, et al. A behavioral test battery for mouse models of Angelman syndrome: a powerful tool for testing drugs and novel Ube3a mutants. Mol Autism. 2018;9:47.","journal-title":"Mol Autism"},{"key":"690_CR46","doi-asserted-by":"crossref","unstructured":"Guyenet SJ, et al. A simple composite phenotype scoring system for evaluating mouse models of cerebellar ataxia. J Vis Exp, 2010(39).","DOI":"10.3791\/1787-v"},{"issue":"5","key":"690_CR47","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.neuron.2013.05.029","volume":"78","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, et al. Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron. 2013;78(5):785\u201398.","journal-title":"Neuron"},{"issue":"7","key":"690_CR48","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.neuron.2021.03.022","volume":"109","author":"DM Ramos","year":"2021","unstructured":"Ramos DM, et al. Tackling neurodegenerative diseases with genomic engineering: A new stem cell initiative from the NIH. Neuron. 2021;109(7):1080\u20133.","journal-title":"Neuron"},{"key":"690_CR49","doi-asserted-by":"publisher","first-page":"108995","DOI":"10.1016\/j.jneumeth.2020.108995","volume":"348","author":"JS Thacker","year":"2021","unstructured":"Thacker JS, et al. Unlocking the brain: A new method for Western blot protein detection from fixed brain tissue. J Neurosci Methods. 2021;348:108995.","journal-title":"J Neurosci Methods"},{"issue":"41","key":"690_CR50","doi-asserted-by":"publisher","first-page":"17668","DOI":"10.1073\/pnas.1004487107","volume":"107","author":"SJ Chamberlain","year":"2010","unstructured":"Chamberlain SJ, et al. Induced pluripotent stem cell models of the genomic imprinting disorders Angelman and Prader-Willi syndromes. Proc Natl Acad Sci U S A. 2010;107(41):17668\u201373.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"690_CR51","doi-asserted-by":"publisher","first-page":"15038","DOI":"10.1038\/ncomms15038","volume":"8","author":"JJ Fink","year":"2017","unstructured":"Fink JJ, et al. Disrupted neuronal maturation in Angelman syndrome-derived induced pluripotent stem cells. Nat Commun. 2017;8:15038.","journal-title":"Nat Commun"},{"issue":"6472","key":"690_CR52","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1126\/science.aav5386","volume":"366","author":"AX Sun","year":"2019","unstructured":"Sun AX, et al. Potassium channel dysfunction in human neuronal models of Angelman syndrome. Science. 2019;366(6472):1486\u201392.","journal-title":"Science"},{"issue":"5","key":"690_CR53","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1038\/s41380-022-01484-z","volume":"27","author":"NJ Pandya","year":"2022","unstructured":"Pandya NJ, et al. A cross-species Spatiotemporal proteomic analysis identifies UBE3A-dependent signaling pathways and targets. Mol Psychiatry. 2022;27(5):2590\u2013601.","journal-title":"Mol Psychiatry"},{"issue":"35","key":"690_CR54","doi-asserted-by":"publisher","first-page":"33067","DOI":"10.1074\/jbc.M212635200","volume":"278","author":"F Zhang","year":"2003","unstructured":"Zhang F, et al. Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J Biol Chem. 2003;278(35):33067\u201377.","journal-title":"J Biol Chem"},{"key":"690_CR55","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.virol.2014.09.007","volume":"468\u2013470","author":"S Sominsky","year":"2014","unstructured":"Sominsky S, et al. HPV16 E6 and E6AP differentially cooperate to stimulate or augment Wnt signaling. Virology. 2014;468\u2013470:510\u201323.","journal-title":"Virology"},{"issue":"12","key":"690_CR56","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1099\/jgv.0.000624","volume":"97","author":"Y Kuslansky","year":"2016","unstructured":"Kuslansky Y, et al. Ubiquitin ligase E6AP mediates nonproteolytic polyubiquitylation of beta-catenin independent of the E6 oncoprotein. J Gen Virol. 2016;97(12):3313\u201330.","journal-title":"J Gen Virol"},{"issue":"4","key":"690_CR57","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/DBP.0b013e31817dc447","volume":"29","author":"E Berry-Kravis","year":"2008","unstructured":"Berry-Kravis E, et al. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr. 2008;29(4):293\u2013302.","journal-title":"J Dev Behav Pediatr"},{"key":"690_CR58","doi-asserted-by":"crossref","unstructured":"McCamphill PK et al. Selective Inhibition of glycogen synthase kinase 3alpha corrects pathophysiology in a mouse model of fragile X syndrome. Sci Transl Med, 2020. 12(544).","DOI":"10.1126\/scitranslmed.aam8572"},{"key":"690_CR59","doi-asserted-by":"publisher","first-page":"792364","DOI":"10.3389\/fnmol.2021.792364","volume":"14","author":"SM Arciniegas Ruiz","year":"2021","unstructured":"Arciniegas Ruiz SM, Eldar-Finkelman H. Glycogen synthase Kinase-3 inhibitors: preclinical and clinical focus on CNS-A decade onward. Front Mol Neurosci. 2021;14:792364.","journal-title":"Front Mol Neurosci"},{"issue":"12","key":"690_CR60","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1111\/bph.15438","volume":"178","author":"YC Ryu","year":"2021","unstructured":"Ryu YC, et al. KY19382, a novel activator of Wnt\/beta-catenin signalling, promotes hair regrowth and hair follicle neogenesis. Br J Pharmacol. 2021;178(12):2533\u201346.","journal-title":"Br J Pharmacol"},{"issue":"5","key":"690_CR61","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/aur.2697","volume":"15","author":"SP Petkova","year":"2022","unstructured":"Petkova SP, et al. Gait as a quantitative translational outcome measure in Angelman syndrome. Autism Res. 2022;15(5):821\u201333.","journal-title":"Autism Res"},{"issue":"1","key":"690_CR62","doi-asserted-by":"publisher","first-page":"8451","DOI":"10.1038\/s41598-017-08825-x","volume":"7","author":"HA Born","year":"2017","unstructured":"Born HA, et al. Strain-dependence of the Angelman syndrome phenotypes in Ube3a maternal deficiency mice. Sci Rep. 2017;7(1):8451.","journal-title":"Sci Rep"},{"issue":"1","key":"690_CR63","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13229-021-00416-y","volume":"12","author":"NA Copping","year":"2021","unstructured":"Copping NA, Silverman JL. Abnormal electrophysiological phenotypes and sleep deficits in a mouse model of Angelman syndrome. Mol Autism. 2021;12(1):9.","journal-title":"Mol Autism"},{"issue":"1","key":"690_CR64","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13229-021-00467-1","volume":"12","author":"EL Berg","year":"2021","unstructured":"Berg EL, et al. Insulin-like growth factor-2 does not improve behavioral deficits in mouse and rat models of Angelman syndrome. Mol Autism. 2021;12(1):59.","journal-title":"Mol Autism"},{"key":"690_CR65","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.bbr.2012.12.052","volume":"243","author":"HS Huang","year":"2013","unstructured":"Huang HS, et al. Behavioral deficits in an Angelman syndrome model: effects of genetic background and age. Behav Brain Res. 2013;243:79\u201390.","journal-title":"Behav Brain Res"},{"issue":"7","key":"690_CR66","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1172\/JCI37873","volume":"120","author":"R Gomez-Sintes","year":"2010","unstructured":"Gomez-Sintes R, Lucas JJ. NFAT\/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 Inhibition in a mouse model of lithium therapy. J Clin Invest. 2010;120(7):2432\u201345.","journal-title":"J Clin Invest"},{"issue":"40","key":"690_CR67","doi-asserted-by":"publisher","first-page":"15641","DOI":"10.1074\/jbc.RA118.002840","volume":"293","author":"W Zhang","year":"2018","unstructured":"Zhang W, et al. Neuron activity-induced Wnt signaling up-regulates expression of brain-derived neurotrophic factor in the pain neural circuit. J Biol Chem. 2018;293(40):15641\u201351.","journal-title":"J Biol Chem"},{"key":"690_CR68","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3389\/fnmol.2019.00289","volume":"12","author":"V Kumar","year":"2019","unstructured":"Kumar V, et al. Simvastatin restores HDAC1\/2 activity and improves behavioral deficits in Angelman syndrome model mouse. Front Mol Neurosci. 2019;12:289.","journal-title":"Front Mol Neurosci"},{"issue":"3","key":"690_CR69","doi-asserted-by":"publisher","first-page":"588","DOI":"10.2337\/diabetes.52.3.588","volume":"52","author":"DB Ring","year":"2003","unstructured":"Ring DB, et al. Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003;52(3):588\u201395.","journal-title":"Diabetes"},{"key":"690_CR70","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1186\/1471-2164-13-635","volume":"13","author":"MB Wisniewska","year":"2012","unstructured":"Wisniewska MB, et al. Novel beta-catenin target genes identified in thalamic neurons encode modulators of neuronal excitability. BMC Genomics. 2012;13:635.","journal-title":"BMC Genomics"},{"issue":"7","key":"690_CR71","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1523\/JNEUROSCI.23-07-02634.2003","volume":"23","author":"EJ Weeber","year":"2003","unstructured":"Weeber EJ, et al. Derangements of hippocampal calcium\/calmodulin-dependent protein kinase II in a mouse model for Angelman mental retardation syndrome. J Neurosci. 2003;23(7):2634\u201344.","journal-title":"J Neurosci"},{"key":"690_CR72","doi-asserted-by":"publisher","first-page":"p3923384","DOI":"10.1155\/2022\/3923384","volume":"2022","author":"J Sun","year":"2022","unstructured":"Sun J, et al. Lack of UBE3A-Mediated regulation of synaptic SK2 channels contributes to learning and memory impairment in the female mouse model of Angelman syndrome. Neural Plast. 2022;2022:p3923384.","journal-title":"Neural Plast"},{"issue":"1","key":"690_CR73","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S0896-6273(01)00194-5","volume":"29","author":"W Lu","year":"2001","unstructured":"Lu W, et al. Activation of synaptic NMDA receptors induces membrane insertion of new AMPA receptors and LTP in cultured hippocampal neurons. Neuron. 2001;29(1):243\u201354.","journal-title":"Neuron"},{"issue":"3","key":"690_CR74","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0896-6273(03)00687-1","volume":"40","author":"M Colledge","year":"2003","unstructured":"Colledge M, et al. Ubiquitination regulates PSD-95 degradation and AMPA receptor surface expression. Neuron. 2003;40(3):595\u2013607.","journal-title":"Neuron"},{"issue":"1","key":"690_CR75","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1038\/s41467-021-23133-9","volume":"12","author":"B Compans","year":"2021","unstructured":"Compans B, et al. NMDAR-dependent long-term depression is associated with increased short term plasticity through autophagy mediated loss of PSD-95. Nat Commun. 2021;12(1):2849.","journal-title":"Nat Commun"},{"key":"690_CR76","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.pharmthera.2014.11.016","volume":"148","author":"E Beurel","year":"2015","unstructured":"Beurel E, Grieco SF, Jope RS. Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol Ther. 2015;148:114\u201331.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"690_CR77","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s002130100871","volume":"158","author":"T Fukumoto","year":"2001","unstructured":"Fukumoto T, et al. Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology. 2001;158(1):100\u20136.","journal-title":"Psychopharmacology"},{"issue":"7","key":"690_CR78","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/S0028-3908(02)00217-4","volume":"43","author":"R Hashimoto","year":"2002","unstructured":"Hashimoto R, et al. Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential step for neuroprotection against glutamate excitotoxicity. Neuropharmacology. 2002;43(7):1173\u20139.","journal-title":"Neuropharmacology"},{"issue":"2","key":"690_CR79","doi-asserted-by":"publisher","first-page":"e1001478","DOI":"10.1371\/journal.pbio.1001478","volume":"11","author":"C Cao","year":"2013","unstructured":"Cao C, et al. Impairment of TrkB-PSD-95 signaling in Angelman syndrome. PLoS Biol. 2013;11(2):e1001478.","journal-title":"PLoS Biol"},{"issue":"1","key":"690_CR80","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1046\/j.1471-4159.2002.00939.x","volume":"82","author":"L Mai","year":"2002","unstructured":"Mai L, Jope RS, Li X. BDNF-mediated signal transduction is modulated by GSK3beta and mood stabilizing agents. J Neurochem. 2002;82(1):75\u201383.","journal-title":"J Neurochem"},{"key":"690_CR81","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.npep.2015.08.005","volume":"54","author":"JW Yang","year":"2015","unstructured":"Yang JW, et al. BDNF promotes the growth of human neurons through crosstalk with the Wnt\/beta-catenin signaling pathway via GSK-3beta. Neuropeptides. 2015;54:35\u201346.","journal-title":"Neuropeptides"},{"key":"690_CR82","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.mcn.2013.04.006","volume":"56","author":"BG Hiester","year":"2013","unstructured":"Hiester BG, et al. Neurotrophin and Wnt signaling cooperatively regulate dendritic spine formation. Mol Cell Neurosci. 2013;56:115\u201327.","journal-title":"Mol Cell Neurosci"},{"issue":"17","key":"690_CR83","doi-asserted-by":"publisher","first-page":"11910","DOI":"10.1074\/jbc.M511920200","volume":"281","author":"J Chen","year":"2006","unstructured":"Chen J, Park CS, Tang SJ. Activity-dependent synaptic Wnt release regulates hippocampal long term potentiation. J Biol Chem. 2006;281(17):11910\u20136.","journal-title":"J Biol Chem"},{"issue":"3","key":"690_CR84","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1101\/lm.6.3.243","volume":"6","author":"WA Gottschalk","year":"1999","unstructured":"Gottschalk WA, et al. Signaling mechanisms mediating BDNF modulation of synaptic plasticity in the hippocampus. Learn Mem. 1999;6(3):243\u201356.","journal-title":"Learn Mem"},{"issue":"Pt C","key":"690_CR85","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.neuropharm.2013.04.005","volume":"76","author":"G Leal","year":"2014","unstructured":"Leal G, Comprido D, Duarte CB. BDNF-induced local protein synthesis and synaptic plasticity. Neuropharmacology. 2014;76(Pt C):639\u201356.","journal-title":"Neuropharmacology"},{"issue":"3","key":"690_CR86","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.nlm.2007.08.018","volume":"89","author":"Y Lu","year":"2008","unstructured":"Lu Y, Christian K, Lu B. BDNF: a key regulator for protein synthesis-dependent LTP and long-term memory? Neurobiol Learn Mem. 2008;89(3):312\u201323.","journal-title":"Neurobiol Learn Mem"},{"issue":"1","key":"690_CR87","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.cmet.2017.06.005","volume":"26","author":"V Nikoletopoulou","year":"2017","unstructured":"Nikoletopoulou V, et al. Modulation of autophagy by BDNF underlies synaptic plasticity. Cell Metab. 2017;26(1):230\u2013e2425.","journal-title":"Cell Metab"},{"issue":"2","key":"690_CR88","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/nn1381","volume":"8","author":"Y Ji","year":"2005","unstructured":"Ji Y, et al. Cyclic AMP controls BDNF-induced TrkB phosphorylation and dendritic spine formation in mature hippocampal neurons. Nat Neurosci. 2005;8(2):164\u201372.","journal-title":"Nat Neurosci"},{"issue":"1","key":"690_CR89","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/hmg\/ddm288","volume":"17","author":"SV Dindot","year":"2008","unstructured":"Dindot SV, et al. The Angelman syndrome ubiquitin ligase localizes to the synapse and nucleus, and maternal deficiency results in abnormal dendritic spine morphology. Hum Mol Genet. 2008;17(1):111\u20138.","journal-title":"Hum Mol Genet"},{"issue":"17","key":"690_CR90","doi-asserted-by":"publisher","first-page":"4888","DOI":"10.1523\/JNEUROSCI.4204-15.2016","volume":"36","author":"H Kim","year":"2016","unstructured":"Kim H, et al. Maternal loss of Ube3a impairs Experience-Driven dendritic spine maintenance in the developing visual cortex. J Neurosci. 2016;36(17):4888\u201394.","journal-title":"J Neurosci"},{"issue":"5\u20136","key":"690_CR91","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/dneu.22757","volume":"80","author":"X Yang","year":"2020","unstructured":"Yang X. Characterizing spine issues: if offers novel therapeutics to Angelman syndrome. Dev Neurobiol. 2020;80(5\u20136):200\u20139.","journal-title":"Dev Neurobiol"},{"issue":"6","key":"690_CR92","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/nn.2327","volume":"12","author":"K Yashiro","year":"2009","unstructured":"Yashiro K, et al. Ube3a is required for experience-dependent maturation of the neocortex. Nat Neurosci. 2009;12(6):777\u201383.","journal-title":"Nat Neurosci"},{"key":"690_CR93","doi-asserted-by":"publisher","first-page":"476","DOI":"10.3389\/fnmol.2018.00476","volume":"11","author":"SJ Lopez","year":"2018","unstructured":"Lopez SJ, Segal DJ, LaSalle JM. UBE3A: an E3 ubiquitin ligase with Genome-Wide impact in neurodevelopmental disease. Front Mol Neurosci. 2018;11:476.","journal-title":"Front Mol Neurosci"},{"issue":"20","key":"690_CR94","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1206524","volume":"367","author":"J de Ligt","year":"2012","unstructured":"de Ligt J, et al. Diagnostic exome sequencing in persons with severe intellectual disability. N Engl J Med. 2012;367(20):1921\u20139.","journal-title":"N Engl J Med"},{"issue":"3","key":"690_CR95","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1007\/s12035-019-01785-5","volume":"57","author":"M Martinez","year":"2020","unstructured":"Martinez M, et al. Canonical Wnt signaling modulates the expression of Pre- and postsynaptic components in different Temporal patterns. Mol Neurobiol. 2020;57(3):1389\u2013404.","journal-title":"Mol Neurobiol"},{"issue":"5","key":"690_CR96","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.neuron.2007.01.029","volume":"53","author":"S Peineau","year":"2007","unstructured":"Peineau S, et al. LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron. 2007;53(5):703\u201317.","journal-title":"Neuron"},{"key":"690_CR97","doi-asserted-by":"publisher","first-page":"114358","DOI":"10.1016\/j.expneurol.2023.114358","volume":"363","author":"X Hao","year":"2023","unstructured":"Hao X, et al. UBE3A deficiency-induced autophagy is associated with activation of AMPK-ULK1 and p53 pathways. Exp Neurol. 2023;363:114358.","journal-title":"Exp Neurol"},{"key":"690_CR98","doi-asserted-by":"crossref","unstructured":"Pan HY, Valapala M. Regulation of autophagy by the glycogen synthase Kinase-3 (GSK-3) signaling pathway. Int J Mol Sci, 2022. 23(3).","DOI":"10.3390\/ijms23031709"},{"issue":"1","key":"690_CR99","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41467-022-28301-z","volume":"13","author":"E Kallergi","year":"2022","unstructured":"Kallergi E, et al. Dendritic autophagy degrades postsynaptic proteins and is required for long-term synaptic depression in mice. Nat Commun. 2022;13(1):680.","journal-title":"Nat Commun"},{"issue":"13","key":"690_CR100","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1038\/emboj.2013.123","volume":"32","author":"KJ Petherick","year":"2013","unstructured":"Petherick KJ, et al. Autolysosomal beta-catenin degradation regulates Wnt-autophagy-p62 crosstalk. EMBO J. 2013;32(13):1903\u201316.","journal-title":"EMBO J"},{"key":"690_CR101","doi-asserted-by":"publisher","first-page":"114869","DOI":"10.1016\/j.expneurol.2024.114869","volume":"379","author":"X Yang","year":"2024","unstructured":"Yang X, et al. Interlinked destinies: how ubiquitin-proteasome and autophagy systems underpin neurocognitive outcomes. Exp Neurol. 2024;379:114869.","journal-title":"Exp Neurol"},{"issue":"5","key":"690_CR102","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1172\/JCI80554","volume":"125","author":"S Silva-Santos","year":"2015","unstructured":"Silva-Santos S, et al. Ube3a reinstatement identifies distinct developmental windows in a murine Angelman syndrome model. J Clin Invest. 2015;125(5):2069\u201376.","journal-title":"J Clin Invest"},{"issue":"37","key":"690_CR103","doi-asserted-by":"publisher","first-page":"8011","DOI":"10.1523\/JNEUROSCI.0083-18.2018","volume":"38","author":"DC Rotaru","year":"2018","unstructured":"Rotaru DC, et al. Adult Ube3a gene reinstatement restores the electrophysiological deficits of prefrontal cortex layer 5 neurons in a mouse model of Angelman syndrome. J Neurosci. 2018;38(37):8011\u201330.","journal-title":"J Neurosci"},{"key":"690_CR104","doi-asserted-by":"publisher","first-page":"103724","DOI":"10.1016\/j.mcn.2022.103724","volume":"120","author":"A Dodge","year":"2022","unstructured":"Dodge A, et al. Recovery of Angelman syndrome rat deficits with UBE3A protein supplementation. Mol Cell Neurosci. 2022;120:103724.","journal-title":"Mol Cell Neurosci"},{"key":"690_CR105","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.neuropharm.2018.10.038","volume":"144","author":"Y Liu","year":"2019","unstructured":"Liu Y, et al. Enhancement of synaptic plasticity and reversal of impairments in motor and cognitive functions in a mouse model of Angelman syndrome by a small neurogenic molecule, NSI-189. Neuropharmacology. 2019;144:337\u201344.","journal-title":"Neuropharmacology"},{"issue":"12","key":"690_CR106","doi-asserted-by":"publisher","first-page":"e1004039","DOI":"10.1371\/journal.pgen.1004039","volume":"9","author":"L Meng","year":"2013","unstructured":"Meng L, et al. Truncation of Ube3a-ATS unsilences paternal Ube3a and ameliorates behavioral defects in the Angelman syndrome mouse model. PLoS Genet. 2013;9(12):e1004039.","journal-title":"PLoS Genet"},{"key":"690_CR107","doi-asserted-by":"crossref","unstructured":"Schmid RS et al. CRISPR\/Cas9 directed to the Ube3a antisense transcript improves Angelman syndrome phenotype in mice. J Clin Invest, 2021. 131(5).","DOI":"10.1172\/JCI142574"},{"issue":"7","key":"690_CR108","doi-asserted-by":"publisher","first-page":"e00734","DOI":"10.1002\/mgg3.734","volume":"7","author":"N Khan","year":"2019","unstructured":"Khan N, et al. Healthcare burden among individuals with Angelman syndrome: findings from the Angelman syndrome natural history study. Mol Genet Genomic Med. 2019;7(7):e00734.","journal-title":"Mol Genet Genomic Med"},{"issue":"5","key":"690_CR109","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.neuron.2020.05.015","volume":"106","author":"ET Kavalali","year":"2020","unstructured":"Kavalali ET, Monteggia LM. Targeting homeostatic synaptic plasticity for treatment of mood disorders. Neuron. 2020;106(5):715\u201326.","journal-title":"Neuron"},{"key":"690_CR110","unstructured":"Behavior and Anxiety in Angelman Syndrome 2021."},{"key":"690_CR111","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12888-015-0490-1","volume":"15","author":"S Serret","year":"2015","unstructured":"Serret S, et al. Lithium as a rescue therapy for regression and catatonia features in two SHANK3 patients with autism spectrum disorder: case reports. BMC Psychiatry. 2015;15:107.","journal-title":"BMC Psychiatry"},{"key":"690_CR112","doi-asserted-by":"publisher","first-page":"650298","DOI":"10.3389\/fphar.2021.650298","volume":"12","author":"J Yuan","year":"2021","unstructured":"Yuan J, et al. Population pharmacokinetics of lithium in young pediatric patients with intellectual disability. Front Pharmacol. 2021;12:650298.","journal-title":"Front Pharmacol"},{"key":"690_CR113","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3389\/fnmol.2018.00425","volume":"11","author":"J Yuan","year":"2018","unstructured":"Yuan J, et al. Lithium treatment is safe in children with intellectual disability. Front Mol Neurosci. 2018;11:425.","journal-title":"Front Mol Neurosci"},{"issue":"5","key":"690_CR114","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1542\/peds.2015-0743","volume":"136","author":"RL Findling","year":"2015","unstructured":"Findling RL, et al. Lithium in the acute treatment of bipolar I disorder: A Double-Blind, Placebo-Controlled study. Pediatrics. 2015;136(5):885\u201394.","journal-title":"Pediatrics"},{"issue":"4","key":"690_CR115","doi-asserted-by":"publisher","first-page":"688","DOI":"10.34172\/apb.2023.071","volume":"13","author":"SR Shri","year":"2023","unstructured":"Shri SR, et al. Role of GSK-3beta inhibitors: new promises and opportunities for alzheimer\u2019s disease. Adv Pharm Bull. 2023;13(4):688\u2013700.","journal-title":"Adv Pharm Bull"}],"container-title":["Molecular Autism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13229-025-00690-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13229-025-00690-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13229-025-00690-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T09:03:34Z","timestamp":1764234214000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularautism.biomedcentral.com\/articles\/10.1186\/s13229-025-00690-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":115,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["690"],"URL":"https:\/\/doi.org\/10.1186\/s13229-025-00690-0","relation":{},"ISSN":["2040-2392"],"issn-type":[{"value":"2040-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"19 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.M. is a founder of Aingeal and received funding for research on depression unrelated to the work reported here. Y.-W.A.H. is a founder of Acre Therapeutics LLC focusing on the therapeutic research and development of antisense oligonucleotides (ASO) for treatments for tauopathies including Alzheimer\u2019s. The remaining authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}